Evidence guide

What published studies ask—and what remains uncertain

Clinical evidence is more than a headline result. This guide organizes recurring research themes around study questions, measured endpoints, participant experience, and the limits that shape interpretation.

Medical Disclaimer: This website provides general scientific and educational information about oral GLP-1 receptor agonists only. The content is based on publicly available clinical trial data and published literature as of the time of writing. Nothing on this website constitutes medical advice, diagnosis, treatment recommendation, or a substitute for professional medical care. The information is not intended to encourage, promote, or facilitate the use of any specific medication. Always consult a qualified healthcare professional before making any decisions related to your health, medications, or treatment. Do not start, stop, or change any medication based on information from this website. The owners and authors of this website assume no responsibility or liability for any consequences arising from the use or interpretation of the information presented here.

On this page Evidence themes Study limits Interpretation

Four recurring evidence themes

These categories describe questions commonly addressed in published literature. They do not establish comparative superiority, predict an individual response, or determine whether treatment is appropriate.

01 / GLYCEMIC ENDPOINTS

How are changes in glycemic measures evaluated?

Question

Does the studied intervention change prespecified measures of glycemic control during the trial period?

What studies examine

Trials may evaluate laboratory-based endpoints, the proportion of participants reaching defined thresholds, changes over time, and findings relative to placebo or an active comparator.

What remains uncertain

Trial averages do not predict an individual result. Findings may also depend on baseline characteristics, background care, adherence, duration, and handling of missing data.

02 / WEIGHT-RELATED ENDPOINTS

What do weight-related outcomes actually show?

Question

How does body weight change within a defined study population and observation period?

What studies examine

Researchers may report average change, categorical thresholds, trajectories across visits, and results under different statistical assumptions.

What remains uncertain

Results cannot be detached from eligibility criteria, co-interventions, discontinuation, follow-up length, or the endpoint’s place in the study hierarchy.

03 / ADHERENCE & USE

How do study conditions affect medication use?

Question

Can participants follow the studied administration conditions, and how consistently is exposure maintained?

What studies examine

Research may document treatment completion, interruptions, discontinuation, protocol adherence, participant-reported experience, and reasons for leaving a study.

What remains uncertain

Adherence observed with trial visits and structured support may differ from routine care. Preference alone does not establish effectiveness or suitability.

04 / PERSISTENCE OF EVIDENCE

How durable and transferable are the findings?

Question

Do findings remain informative beyond the trial’s selected population, controlled setting, and scheduled follow-up?

What studies examine

Longer observation, extension studies, post-trial follow-up, subgroup analyses, and evidence from routine clinical settings may address different parts of this question.

What remains uncertain

Short studies cannot establish long-term outcomes. Subgroup findings may be exploratory, and real-world data can introduce confounding and incomplete measurement.

Study limits

Questions to keep beside every result

Limitations do not automatically invalidate a study. They define the boundary within which a finding can be interpreted responsibly.

Who was included?

Eligibility criteria can produce a study population that differs from people encountered in broader clinical practice.

What was the comparator?

Placebo, active-comparator, and non-comparative designs answer different questions and should not be read interchangeably.

How long was follow-up?

The duration of observation limits conclusions about durability, delayed effects, and outcomes after discontinuation.

How were missing data handled?

Attrition and statistical assumptions can affect estimates, particularly when discontinuation differs across study groups.

Was the endpoint prespecified?

Primary, secondary, and exploratory analyses carry different evidentiary weight. Multiple comparisons can complicate interpretation.

Who funded and conducted the work?

Funding, investigator roles, protocol access, publication status, and conflicts of interest belong in a complete appraisal.

From result to responsible interpretation

A statistically reported difference and a clinically meaningful conclusion are related questions, but they are not the same question.

What evidence can support

A carefully bounded statement about outcomes observed in a defined population, under specified study conditions, over a stated period, using prespecified analyses.

What evidence cannot decide alone

Which route or medication is “best,” whether a result will apply to one person, or whether any intervention is appropriate. Those are clinical decisions requiring individualized professional care.

Source status

Supporting references for these evidence themes: Insert peer-reviewed source. Bibliographic placeholders and the last-reviewed date are maintained on the Sources page.

Review source notes